Recently increased evidence from multiple randomized control studies have shown that drugs mimicking the physiological incretin effect on insulin secretion provide better and effective blood sugar control in obese diabetics, Dr Ahluwalia says.
Incretin hormone secretion and actions are impaired in type 2 diabetes. Also beta cell responsiveness to GLP - 1 is reduiced, but exogenous GLP - 1 can still restore beta cell sensitivity to glucose and improve glucose induced insulin secretion.
One such drug called Exenatide (Byetta), which is a synthetic version of salivary protein found in the gila monster, binds to human GLP - 1 receptors on beta cells in vitro. Such incretin based therapies of type 2 diabetes may be expected to reduce hyperglycemia and HbA1c levels, improve alpha cell and beta cell function, improve insulin sensitivity and improve metabolism.
Exenatide is not beneficial for every type 2 duabetic patient. Patient selection is very important before starting exanatide. It is primarily indicated in the following situations:
1. BMI > 30
2. HbA1c > 8.5 on 2/3 antidiabetic drugs
3. not willing for SMBG
4. always feels hungry
5. wants to lose weight
6. anxious about hypoglycemia with insulin.
As with insulin, Exenatide has to be injected subcutaneously once or twice daily. Main side effects include nausea, diarrhea and pancreatitis (0.3 cases in 1000 patients). By Dr. Vikas Ahluwalia
Source-ANI
RAS